DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS : CHARACTERIZATION OF A HUMORAL IMMUNOSUPPRESSIVE FACTOR by Brooks, William H. et al.
DEPRESSED  CELL-MEDIATED  IMMUNITY  IN  PATIENTS 
WITH  PRIMARY  INTRACRANIAL  TUMORS 
CHARACTERIZATION  OF  A  HUMORAL  IMMUNOSUPPRESSIVE  FACTOR* 
BY WILLIAM H.  BROOKS,:~ MARTIN G.  NETSKY, DAVID E.  NORMANSELL, 
AND DAVID A. HORWITZ§ 
(From  the  Departments  of Internal  Medicine,  Pathology,  and  Microbiology, 
University of Virginia  School of Medicine,  Charlottesville, Virginia  22903) 
(Received for publication 18 August 1972) 
Impaired cell-mediated immunity in certain patients with nonlymphoid cancer is 
indicated by depressed skin reactivity to common antigens (1, 2), delayed homograft 
rejection  (3),  decreased  ability  to become sensitized  to  dinitrofluorobenzene  (4)  or 
dinitrochlorobenzene  (5, 6),  and decreased in vitro lymphocyte responsiveness to the 
mitogen phytohemagglutinin (7, 8). It is not known whether  depressed  cell-mediated 
immunity precedes or follows the development of cancer. 
Tumor-specific antigens and  cell-mediated  tumor immunity are noted in cases of 
human cancer. Blood lymphocytes from patients with some neoplasms inhibit tumor 
cell growth (9, 10) or undergo blast transformation when cultured with autochthonous 
tumor cells  (11). In addition to the cell-mediated responses, the sera of these patients 
contain antibodies or antigen-antibody complexes (12) that specifically block lympho- 
cyte-tumor cell interaction through a poorly understood phenomenon termed immuno- 
logic enhancement (13,  14). 
In  the  present  studies,  patients  with  primary  intracranial  tumors  were 
found to have  depressed  cell-mediated  immunity.  Unlike  other patients  with 
solid systemic tumors and impaired delayed  hypersensitivity,  our  patients  did 
not have clinical evidence of metastases,  weight loss, or hematologic  abnormal- 
ities.  These  patients,  then,  afforded  an  unusual  opportunity  to  study  host 
mechanisms responsible for defective cell-mediated immunity. 
Although  delayed  hypersensitivity  and  other  cell-mediated  responses  were 
depressed,  we found evidence  of lymphocyte sensitization  to  tumor  antigens. 
To  clarify  these  apparently  paradoxical  findings,  we  evaluated  mononuc]ear 
leukocyte function with  the  one-way mixed  lymphocyte  reaction.  Cellular  re- 
activity in the  absence of patient plasma  was  normal.  Such plasma,  however, 
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strongly,  suppressed  lymphocyte  blast  transformation.  Immunosuppressive  ac- 
tivity  was  found  in  IgG  fractions  isolated  from  patient  sera. 
Materials  and Methods 
23  patients  with  benign  and  malignant  intracranial  tumors  were  studied  (Table  I).  15 
were men and  8  were women;  ages ranged from 10 to 69 yr  (median  =  48).  Patients  were not 
receiving corticosteroids,  cytotoxic drugs, or radiation  therapy  at the time they were studied. 
All venipunctures  were  performed  before  skin  tests  or  blood  transfusions.  Healthy  hospital 
employees  served  as  controls.  10  were  men  and  10  were  women;  ages  ranged  from  24  to  63 
years  (median  =  41). 
Skin  Testing .for Delayed  Hypersensitiv#y.--All  subjects  were  skin  tested  by  intradermal 
injections of 0.1  ml  of  the following antigens:  intermediate  strength  purified protein  deriva- 
TABLE  I 
Clinical  Data,  Skin-Test Reactivity,  and  Leukocyte  Response  to  Phytohemagglutinin 
of Patients with Inh'aeranial  Tumors 
Clinical information  Skin tests* 
PHA 
Patient  Age  Sex  Diagnosis  HCT  WBC  SL  DNCB  PPD  SK SD  CAND  TRICH 
yr  cpm 
Group  I:  Nonresponders 
M.S.  69  F  Glioblastoma  40  10,500 
W.H.  52  M  Glioblastoma  40  11,500 
A.D.  52  F  Glioblastoma  39  1(l,500 
W.K.  26  M  Astrocytoma  44  6,800 
N.T.  5(I  F  Hemangio-  45  7,400 
blastorna 
G.R.  10  M  Medullo-  45  8,100 
blastoma 
R.C.  14  M  Ependy-  48  7,500 
moma 
G.M.  52  F  Meningioma  40  9,500 
M.G.  48  F  Meningioma  42  7,500 
A.D.  26  M  Neuroma  47  11,100 
L.R.  65  F  Neuroma  41  7,500 
to  DNCB  or  skin-test  antigens 
3090  0  0  0  0  0  7,250 
1495  0  0  0  0  0  37,333 
1685  0  NT  NT  NT  NT  NT 
1297  0  0  4  0  0  12,243 
1702  0  0  {}  0  0  15,374 
I700  0  0  0  0  0  14,381 
1275  0  0  0  0  0  4,979 
2300  0  0  0  0  0  54,634 
1482  0  0  0  0  0  28,184 
2442  0  0  0  0  0  20,929 
2325  0  0  0  0  0  5,501 
Group II: Nonresponders to DNCB with one positive skin test 
G.R.  54  M  Olioblastoma  45  9,600  3552  0  0  8  0  0  7,092 
T.B.  61  M  Olioblastoma  41  11,500  276(I  0  0  5  0  0  14,935 
J.H.  27  M  Astrocytoma  42  10,500  1785  0  0  5  0  0  2,433 
Group III: Responders  to DNCB  or two or more positive skin tests 
J.K.  42  M  Glioblastoma  40  8,500  1800  +  5  !~  0  7  42,002 
G.C.  39  M  Astrocytoma  41  5,400  972  +  4  10  0  0  16,301 
S.D.  57  M  Astrocytoma  42  7,800  1568  0  0  22  12  0  14,909 
Z.W.  54  F  Astrocytoma  47  10,500  1892  +  0  5  0  0  27,211 
J.J.  12  F  Astrocytoma  39  10,500  2100  +  0  lO  12  0  17,804 
H.S.  25  M  Pinealoma  41  13,400  2268  +  0  8  6  8  73,282 
C.F.  42  M  Pituitary  45  10,500  2450  +  0  12  0  0  28,570 
R.C.  43  M  Pituitary  4I  8,500  2125  NT  0  12  6  0  43,183 
W.I).  48  M  Meningioma  48  9,500  1825  +  0  18  6  4  14,799 
* Mean diameter of induration after 48 hr,  in millimeters. 
Abbreviations used:  [ICT  -  hematocrit; WBC  -  white blood count; SL -  small lymphocytes; DNCB  - 
dinitrochlorobenzene;  PPD  -  tuberculin; CAND  -  Candida; TRICH  -  trichophyton; PHA  =  phytohemag 
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tive  (PPD)l-tuberculin 5  units/0.1  ml  (Dept.  H.  E.  W.,  Tuberculosis Branch,  Atlanta); 
Candida  1  : 10  (Hollister-Stier Laboratories,  Yeadon,  Pa.) ;  trichophyton  1  : 10  (Hollister- 
Sfier), and streptokinase 50 units-streptodornase 10 units ([SK-SD],  Varidase; Lederle Lab- 
oratories, Pearl River, N. Y.). Induration was measured after 5, 24, and 48 hr to discriminate 
between immediate and delayed reactions. 
Sensitization with dinitrochlorobenzene (DNCB) was performed by the method of Cata- 
lona et al.  (6). DNCB was dissolved in acetone to make a stock solution of 2000/~g/0.1  ml. 
Solutions were refrigerated and replenished every 2 wk.  At the time of sensitization, 2000 
/~g were placed on the volar aspect of the forearm and covered with a sterile gauze bandage. 
50 and 100/zg were simultaneously applied to the other forearm to test for prior sensitization. 
Test sites were examined at 24 hr, 7 days, and 14 days. Subjects demonstrating either a spon- 
taneous flare or a flare  24 or 48 hr after a subsequent challenge dose of 50 and 100/zg  were 
designated responders. Subjects not responding after single or repeated application(s) were 
nonresponders. 
Lymphocyte  Tdr3H Incorporation  in Response to Antigens and  Phytohemagglutinin  (PHA ). 
--Washed blood leukocytes  (2.5 X  106) were cultured in triplicate with antigens or PHA, 
using a  modification of previously described techniques (15). The cells were suspended in 3 
ml of minimal essential medium (MEM-S; Grand Island Biological Co., Grand Island, N. Y.) 
containing 20% heat-inactivated type AB  human serum obtained from a  single  donor and 
were cultured in  12  X  75  mm plastic culture  tubes  (Falcon Plastics, Los Angeles,  Calif.). 
Preservative-free PPD was obtained from Parke, Davis & Co., Detroit, Mich. All other anti- 
gens were dialyzed 48 hr before use to remove preservatives. 0.1  ml of each of the following 
was used for culture: phytohemagglutinin-M (PHA)  (lot number 564590 Difco Laboratories, 
Inc.,  Detroit,  Mich.)  1:10;  SK-SD  undiluted;  trichophyton  1:150;  Candida  1:100;  and 
PPD 300/zg/ml. Cultures containing PHA were incubated for 4 days; all other cultures were 
incubated for 6 days at 37°C  (5% CO2). 2 hr before termination, 5 #Ci of tritiated thymidine 
(Tdr3H)  (New  England  Nuclear  Corp.,  Boston,  Mass.;  specific  activity 0.67  Ci/mmole) 
were added to each tube. Samples were then prepared for liquid scintillation counting accord- 
ing to the method of Horwitz, Stastny, and Ziff  (15). A  positive response to antigens was 
defined as at least a  threefold increase of Tdr3H uptake compared with unstimulated cells. 
The cpm of PHA-stimulated leukocytes from controls were consistently 100  times that of 
unstimulated cells. 
Mixed  Lymphocyte-Tumor  Cultures.--Primary  intracranial  tumors  were  obtained  at 
craniotomy,  minced with  scalpel  blades,  and  explanted into several 75-cm  2 plastic  flasks 
(Falcon Plastics No.  3024).  Nutrient  mixture  F-12  (Grand  Island Biological  Co.)  supple- 
mented  with  penicillin  100  units/ml,  streptomycin 50  /zg/ml,  and  20%  heat-inactivated 
fetal calf serum was used as the culture medium. When adequate growth was observed, usu- 
ally  in  14-21  days,  cells  were harvested with 0.025%  trypsin-EDTA  (Grand  Island  Bio- 
logical Co.), washed twice with media (100 g for 10 rain),  and resuspended in a concentration 
of 4 X  105  cells/ml. Tumor  cells were not treated with mitomycin C. 
Lympbocytes to be used as "responder" cells were obtained by concentrating leukocyte- 
rich plasma to 2-4 ml and layering 1 ml on 2.5 ml of 20% sodium Hypaque (Sterling-Winthrop 
Research Inst., Rensselear, N. Y.). After centrifuging at 2500 g for 10 rain at 25°C, the super- 
natant was decanted and washed three times in MEM-S (150 g for 10 min). The cells were re- 
suspended in a  concentration of 6 X  10  ~ mononuclear cells/ml. Differential counts revealed 
80%  lymphocytes (range  70-85~-),  18%  monocytes (range  10-26•),  and  1-2% polymor- 
1 Abbreviations  used in this paper:  DNCB, dinitrochlorobenzene; MEM, minimal essential 
medium;  MLC,  mixed  lymphocyte  culture;  MLTC,  mixed  lymphocyte-tumor  culture; 
PHA, phytohemagglutinin; PPD, purified protein derivative; SK-SD, streptokinase-strepto- 
dornase; Tdr3H, tritiated thymidine. 1634  CHARACTERIZATION  O:F  AN  IMMUNOSUPPRESSIVE  :FACTOR 
phonuclear leukocytes. Cells  stained by trypan blue were rare  (< 1%).  Cultures containing 
1 ml of stimulator cells and 1 ml of responder cells in 20% fetal calf serum were incubated for 
6 days, then isotopically labeled and prepared for scintillation counting as before. 
Suspensions of tumor cells were also placed on glass cover slips in Leighton culture  tubes 
(H.  W.  Leighton Laboratories, Glen  Ridge, N.  J.),  and were subsequently used for histo- 
logic study to determine contamination by fibroblasts. Slides stained with hematoxylin-eosin 
and phosphotungstic acid were reviewed by one of us,  (M.  G. N.). Contamination with fibro- 
blasts was not considered significant. Control cultures  were prepared with autologous fibro- 
blasts from skin or dura, and with fetal brain. These tissues were explanted, cultured  (using 
the previously described techniques), and  used as  the "stimulator" in  mixed lymphocyte- 
tumor reactions (MLTC). 
In some experiments, responder lymphocytes were irradiated with 2500 R  (106 R/rain) 
(Picker Vanguard  (Picker X-ray Corp., Cleveland, Ohio), 280  kvp,  cone size  15  X  20  cm) 
before MLTC.  In other experiments, heat-inactivated autologous and  normal human sera 
were substituted for fetal calf serum. 
Mixed Lymphocyte Cultures.--Mixed lymphocyte cultures  (MLC)  were prepared by  the 
method of Bach and Voynow (16). Responder lymphocytes were obtained as previously de- 
scribed. Stimulator cells were collected from sedimented venous blood, washed three times 
in MEM-S (150 g for 10 min), and incubated at 37°C for 25 min with 25 #g/ml of mitomycin C 
(lot  number  7090 Nutritional  Biochemicals Corp.,  Cleveland,  Ohio).  The  cells  were  then 
washed three more times and adjusted to 4 X  105 leukocytes/ml. Each "one-way" culture 
contained 6 X  l0  s  responder cells,  4  X  l0  s  stimulator cells  in  2.5  ml  MEM-S  containing 
20% human plasma. Triplicate cultures were harvested at 6 days. 
One person (W.  H.  B.)  served as the source  of stimulator cells in all experiments. As a 
positive control, responder cells from normal persons were included in each study with patient 
responder cells. To exclude a  two-way response, PHA was added to mitomycin-treated W. 
H.  B.  stimulator cells.  Uptake of Tdr2H  was not increased in  these cultures.  In some ex- 
periments, the effect of patient plasma was compared with normal plasma on the reactivity 
of both patient and normal responder cells in the MLC. All plasmas were centrifuged at 1400 
g for 20 min at 4°C to remove platelets. 
Identification of Humoral Blocking Factors.--Serum from normal volunteers and from pa- 
tients was dialyzed twice against 0.01  M potassium phosphate buffer, pH 8.0,  and  applied 
to a column of DEAE cellulose  (Whatman DE52, H. Reeve Angel & Co., Inc., Clifton, N. J.) 
previously equilibrated with  this buffer.  Protein not adsorbed to  the column under  these 
conditions was  concentrated  to  the  original  serum  volume,  dialyzed  against  phosphate- 
buffered saline, pH 7.3, and passed through a Millipore filter (0.45 #)  (Millipore  Corp., Bed- 
ford, Mass.). These eluates contained only IgG, as judged by immunoelectrophoresis against 
polyvalent anti-whole human serum (Meloy, Springfield,  Va.). Further analysis by quantita- 
tive immunodiffusion plates (Meloy)  indicated that the eluates studied contained only IgG; 
no  other  immunoglobulin classes  could  be  detected. 
Cultures were prepared  to  evaluate  the  effect of  patient IgG fractions on  lymphocyte 
activation by  PHA and in MLC.  To  study this effect in  MLC,  0.1-5  mg/ml of IgG was 
added  to cultures containing 20%  normal plasma,  W.  H.  B.  stimulator cells,  and  normal 
responder cells.  Similar  concentrations of  IgG  were  added  to  cultures  containing normal 
leukocytes and PHA. Patient IgG was compared with equal concentrations of normal IgG. 
RESULTS 
Comparison  of Delayed and In  Vitro Hypersensitivity of Tumor Patients and 
Conlrols.--All  control subjects tested could be sensitized to DNCB  (Table II), 
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positive response. In contrast,  only 7 of 22 patients with benign and malignant 
tumors  could  be sensitized  to DNCB.  Reapplication  was necessary  in  all  but 
one of the patient responders. 
When  control  subjects  were  skin  tested  with  PPD,  SK-SD,  Candida,  and 
trichophyton,  all  responded  to  at  least  two  antigens.  Patients  were  signifi- 
cantly less responsive to at least three of the four skin-test antigens  (Table II). 
They were  divided  into  three  groups  on  the  basis  of  the  findings  (Table  I). 
Group I  (11  patients)  and group II (3 patients)  were unresponsive  to DNCB. 
TABLE  II 
Comparison of Delayed Hypersensitivity and Lymphocyte Proliferative Reactivity of Patients 
and Controls 
No. of responders 
Normals  Patients 
P value* 
Delayed hypersensitivity* 
Sensitization  to DNCB  8/8  7/22  0.001 
Response to common antigens 
PPD  8/15  1/22  0. 001 
SK-SD  14/15  11/22  0.006 
CAND  6/15  5/22  >0.1 
TRICH  7/15  1/22  0.004 
Lymphocyte proliferative reactivity 
PHA response§  16/16  17/22  >0.1 
Response to common antigensll 
PPD  11/16  6/23  0.01 
SK-SD  14/15  10/23  0.002 
CAND  5/15  2/23  >0.05 
TRICH  2/16  0/23  >0.1 
* Fisher exact probability test. 
:~ Greater than 5 mm induration at 48 hr. 
§ Greater than 100-fold increase in TdrYH uptake over unstimulated values. 
l] Greater than threefold increase in Tdr3H uptake over unstimulated values. 
Group I  was anergic to the four skin-test  antigens,  and group II patients  had 
one positive skin  test.  Group III included  seven patients who were sensitized 
to DNCB  and two others with two positive skin  tests. As in previous studies, 
SK-SD  yielded  the  greatest  number  of positive  responders  and  the  strongest 
reactions  observed  (17).  Nonetheless,  the  intensity  of  the  48-hr  reaction  in 
group III patients  (mean  12 mm, range 5-22  mm) was significantly less  than 
in the controls  (mean  19 ram, range 8-60 mm) (P  <  0.01). 2 
Delayed  hypersensitivity  in  the  patients  was  impaired,  although  their 
physical condition  was good. They did not have symptoms suggesting general 
debilitation,  nor had they lost weight. There was no anemia, granulocytopenia, 
or lymphopenia  (Table I). 
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The lymphocyte proliferative response to common antigens, as estimated by 
measuring  the  incorporation  of  Tdr-3H,  paralleled  the  skin-test  results.  Sig- 
nificantly fewer  patients  responded  to  PPD  and  SK-SD  when  patients  and 
controls were  compared (Table II). A  significant difference in  the blastogenic 
response to PHA was not observed. Five patients in groups I  and II, however, 
had depressed PHA response (Tables I  and II). 
Lymphocyte  Tdr-3H  Incorporation  in  Response  to  A utochlhonous  Tumor 
Cells.--Increased  incorporation  of  Tdr-3H  was  observed  in  patient  lympho- 
cytes when they were cultured with autochthonous tumor cells in media supple- 
mented with fetal calf serum. In 11 of 13 patients, DNA synthesis in the mixed 
15q-nphocyte-tumor  cell culture was  at  least  twofold greater  than  the  sum  of 
lymphocyte and  tumor  cells cultured  separately.  The  lymphocyte reactivity 
of group I  patients was similar to that of group III patients  (TabIe III). 
In  some  cultures,  lymphocytes irradiated with  2500  R  were  cultured  with 
tumor  cells. Tdr-3H  uptake  was  reduced  to  background  levels. These  results 
excluded the possibility that  tumor cells were stimulated to proliferate in  the 
presence of autologous lymphocytes. 
Increased  Tdr-3H  uptake  was  not  observed  when  lymphocytes  were  cul- 
tured  with  fetal  brain  or  autologous  fibroblasts.  These  results  indicate  spe- 
TABLE III 
Lymphocyte  Recognition of Tumor  Antigens  on  Autochthonous Cells by Mixed  Lymphocyte- 
Tumor Culture (MLTC) 
Skin test 
Patient  Group  Diagnosis 
BKG*  Tumor  cells:~  MLTC  R.I.§ 
cj~m 
M.S.  I  Glioblastoma  537  81  2649  4.1 
W.H.  I  Glloblastoma  165  50  3348  15.5 
N.T.  I  Hemangioblastoma  138  76  449  2.1 
R.C.  I  Ependymoma  131  93  1076  4.8 
G.M.  I  Meningioma  202  313  1376  2.6 
M.G.  I  Meningioma  105  134  479  2.9 
A.D.  I  Neuroma  152  72  1229  5.5 
T.B.  II  Glioblastoma  366  151  815  1.5 
J.H.  II  Astrocytoma  283  895  5006  4.3 
J.K.  III  Glioblastoma  262  179  961  2.2 
G.C.  III  Astrocytoma  196  59  1647  6.5 
Z.W.  III  Astrocytoma  264  566  1535  1.8 
J.J.  III  Astrocytoma  404  215  2698  4.4 
Cells cultured in 20% fetal calf serum. 
* cpm/6 X  105 unstinmlated lymphocytes. 
cpm/4 X  105 tumor cells. 
MLTC  § 
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cific sensitization of autologous lymphocytes to  tumor-associated antigens on 
the surface of tumor cells. 
Table IV indicates the  results of  studies in which human serum was  sub- 
stituted for fetal calf serum. Autologous serum consistently inhibited l)Tnpho- 
cyte activation by autochthonous tumor cells in comparison with simultane- 
ous cultures with normal human serum. Inhibitory activity was greater in the 
serum of group I  (anergic) patients than in group III patients, although these 
differences  were  not  statistically  significant. 
Lymphocyte  Tdr-~H  Incorporation  in  Response  to  Allogeneic  Mononuclear 
Leukocytes.--Patient  lymphocytes cultured in autologous plasma incorporated 
significantly less Tdr-3H than control lymphocytes cultured in normal plasma 
in  the  one-way  MLC  (P  <  0.01)  (Fig.  1).  However,  reactivity  of  patient 
l)azlphocyte  increased  to  normal  values  when  cultured  in  normal  plasma. 
Similarly, suppression of 1)maphocytes from healthy controls was  consistently 
observed in cultures containing patient plasma  (Fig.  1).  Suppressor  activity 
was not affected by heating plasma at 56  ° C for 30 rain or by storage at -  20  ° C' 
for 2 months. 
The  suppression was  proportional to  the  concentration of  patient plasma 
TABLE IV 
The Effect oj Autologous Serum  on  Cell-Mediated Reactivity to  Tumor-Speclfic Antigens  in 
Mixed Lymphocyte-Tumor Culture 
Skin test 
Patient  Group 
Autologous*  Normal*  Inhibition+  + 
cpm  % 
M.S.  I  715  1371  48 
W.H.  I  22  909  97 
N.T.  I  66  193  65 
R.C.  I  991  1809  44 
G.M.  I  518  6040  89 
M.G.  I  24  156  85 
A.B.  I  97  0  0 
T.D.  II  0  180  100 
J.H.  II  2625  4919  45 
J.K.  III  110  344  67 
G.C.  III  89  170  48 
Z.W.  III  1122  1878  40 
J.J.  III  722  1966  63 
* Each value indicates net cpm as determined by subtracting cpm of unstimulated leuko- 
cytes in autologous or normal serum from cpm in culture containing the same serum. Tdr-3H 
uptake  by nonstimulated  lymphocytes was  the  same in cultures  with autologous serum 
(mean 260 cpm, range 112-378 cpm) and homologous serum (mean 295 cpm, range  124-415 
cpm). 
cpm in normal serum -- cpm in autologous serum 
:~ % inhibition = 
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FIG.  l. The effect of plasma on cellular reactivity in the one-way mixed lymphocyte cul- 
ture. W. H. B. "stimulator" cells were used in all studies. Solid lines show simultaneous cul- 
tures containing either patient  or  normal plasma.  P  values were  determined by analysis of 
variance. 
in the culture (Fig. 2). In the instance illustrated, plasma J.J. suppressed the 
activation  of  patient  T.B.'s  lymphocytes  in  MLC. 
MLC  suppressor  activity in  patient  plasma  disappeared  shortly  after the 
removal of the tumor. Fig. 3 indicates that the plasma of patient R. C. com- 
pletely inhibited his  lymphocyte reactivity to allogeneic cells before craniot- 
amy.  One  month  after  surgery,  suppressor  activity  was  no  longer  present. 
In  this study the reactivity of washed lymphocytes after surgery was  almost 
twofold greater than before the tumor was removed. 
Lymphocyte  Suppressor  A ctiz'ity In  Vitro  and  Delayed  Hypersensitivity  In 
Vivo.--Leukocytes  from five patients were stimulated with  PHA in  cultures 
containing  either  autologous  or  normal  serum.  In  all  instances  autologous 
serum inhibited Tdr-aH incorporation (mean inhibition 44%, range 23-66 %). 
Plasma from five group I  (anergic) patients strongly suppressed MLC reac- 
tivity  of  autologous  lymphocytes  (mean  inhibition  92%).  Significantly  less 
suppressor activity was  observed when mononuclear leukocytes of group III 
patients were cultured in  autologous plasma  (mean 63%)  (P <  0.05)  (Table 
V). 
Immunochemical  characterization of a Suppressor of Lymphocyte  A clivalion.-- 
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TABLE V 
Plasma Suppression  of Cellular  Reactivity  In  Vitro  Compared  with Cutaneous 
Reactivity  to  DNCB  and  Common  Antigens 
One-way mixed lymphocyte culture 
Patient  Inhibition** 
Autologous*  Normal* 
cpm 
Group  I  skin  reactions  (nonresponders) 
W.H.  593  2937  80 
A.D.  23  26)4  99 
R.C.  72  1409  95 
G.M.  188  2539  93 
M.G.  176  1886  91 
Mean  210  2289  92~ 
P  <  0.01  P  <  0.05 
Group III skin reactions  i 
J.K.  407  1328  67- 
J.J.  3279  8069  59 
H.S.  5732  8982  36 
R.C.  1266  2805  55 
W.D.  232  3585  98 
Mean  2183  4954  63 
t  _I 
P  >  0.05 
Groups defined in Table I. 
P  values determined using Wilcoxon Rank Sum Test (41). 
* Each  value  indicates net  cpm  as  determined  by subtracting cpm  of  unstinmlated 
leukocytes in autologous  or homologous plasma from cpm in  stimulated culture containing 
the same plasma. 
cpm in normal plasma -- cpm in autologous plasma 
:~ ~f4 inhibition =  X  100. 
cpm in normal plasma 
responder cells in  MLC  is shown  in  Fig. 4.  The  blastogenic response of W.J. 
cells was completely suppressed by 100/zg/ml of IgG from patient J.H. Other 
normal cells (E.P.) were equally suppressed by this concentration of this IgG. 
Similar results were  obtained with  the  IgG fractions  of  three  other  patients 
when  compared with equivalent amounts  of normal IgG isolated at  the same 
time. 
Patient  IgG  also  modified  lymphocyte  stimulation  by  PHA.  1  mg/ml  of 
IgG from J.H. significantly reduced the response of normal (W.J. and W.H.B.) 
lymphocytes to PHA. Lymphocyte activation by PHA was totally suppressed 
by increasing the  level of patient IgG  to  2.5  mg/ml,  whereas  this concentra- 
tion of normal IgG resulted in only 30%  suppression (Fig. 5). 
To  test for possible cytotoxic effects of the fractions, we added suppressive 
concentrations of patient lgG to normal lymphocytes and rabbit complement, 
using  a  standard  macromethod  (18).  Trypan  blue  viability  studies,  after 
incubation  at 37°C  for  1  hr,  indicated less  than  5%  stained  cells. BROOKS~  NETSK¥~ NORMANSELL~ AND  HORWITZ  1641 
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DISC US  SION 
The most significant finding to emerge from the present experiments is that 
the expression from cell-mediate dimmunity may be broadly modified by IgG 
fractions of serum from patients with primary intracranial tumors. Initially we 
found impaired delayed hypersensitivity in patients with benign or malignant 1642  CHARACTERIZATION OF  AN  IMMUNOSUPPRESSIVE  FACTOR 
tumors. Experiments were than designed to test cellular reactivity and humoral 
modifying factors separately. 
In  the first series of experiments, cellular reactivity to a  variety of stimu- 
lants was tested in cultures containing a single source of normal human  serum. 
Lymphocyte transformation to soluble antigens was decreased and this  finding 
correlated with cutaneous anergy. Leukocytes from one-third of patients  who 
could not be sensitized to DNCB  (groups I  and II) responded poorly  to PHA, 
but all patients in group III responded normally to this mitogen. In  contrast 
to the findings in studies with soluble antigens, the mixed lymphocyte cultures 
were normal when patients' mononuclear cells  reacted to  membrane antigens 
on allogeneic cells. 
Secondly, we demonstrated sensitization of patients' lymphocytes to tumor- 
associated antigens in the mixed lymphocyte-tumor cell  reaction. These find- 
ings  are  in  agreement  with  those of Levv and  coworkers, who used  another 
method (19). In addition, the present studies indicated that lymphocytes from 
group I  patients responded to tumor cells  as well as did those from group III 
patients.  Although  the  exwession of delayed hypersensitivity was  impaired, 
there was no intrinsic defect in the patients'  tymphocytes, at least in ability 
to recognize and respond to membrane antigens. 
The  next  series  of  experiments  indicated  that  patients'  sera  consistently 
blocked cell-mediated tumor immunity. This specific blocking or "enhancing" 
activity occurs  in  animal  and  human  neoplasms,  and  has  been  recently re- 
viewed  by  the  Hellstr6ms  (20).  Of greater  interest,  we found  that  the  IgG 
fraction of patients' sera suppressed the blastogenic response of both patients' 
and normal lymphocytes to  PHA and  to  histocompatiblity  antigens on allo- 
geneic  mononuclear  cells.  Further,  quantitatively  more  MLC  suppressor 
activity was  found in anergic patients  than  in others with milder degrees of 
cutaneous  hyporeactivity.  These  studies  suggest  that  enhancing  sera,  in 
addition  to  specifically  blocking  tumor  immunity,  may  broadly  and  non- 
specifically'  suppress  moncnuclear celhflar reactivity. A  sufficient serum  con- 
centration  of  suppressor  factor  may  thus  eventually  impair  host  immuno- 
competence. 
The cell type inhibited  by the humorat  agent is not known.  Macrophages 
are  required  for  the  activation  of lymphocytes in  vitro  (21).  Human  blood 
contains  macrophages  (monocytes) and  other macrophage precursors  as  well 
as lymphocytes (22). Humoral factors interfering with  the function of either 
lymphocytes or macrophages may suppress the MLC. The possibility of dys- 
function  of macrophages  is  not  excluded  by  these  studies.  A  recent  report, 
however,  indicates  that  macrophages  obtained  from  anergic  persons  permit 
purified  lymphocytes from  healthy  persons  to  function  normally  (23).  It  is 
thus likely that the inhibitor in patients' sera directly suppresses lymphocyte 
activation. 
Serum  inhibitors  of  lymphocyte activation  in  cancer patients  have  been BROOKS,  NETSKY,  NORMANSELL,  AND  HORWITZ  1643 
described previously (7, 24, 25), but these have not been characterized. Alpha 
globulin has been found to inhibit lymphocyte activation (26). In one study, 
serum alpha globulin concentration correlated with depressed PHA reactivity 
in patients with cancer of the colon (27), but this finding was not confirmed 
(28). In our studies to date, we have found significant suppressor activity only 
in the first peak of DEAE cellulose chromatography where IgG was the only 
protein detectable. 
Isolation of the suppressor factor in the IgG fraction of patients'  sera sug- 
gests  that  the  active material  is  an  antibody. These molecules may directly 
inhibit  lymphocyte function.  Antibodies  directed  against  light  chain  deter- 
minants of immunoglobulin (29)  and against HL-A antigens suppress the ac- 
tivation of responder lymphocytes in MLC. Poor correlation was noted between 
the  HL-A specificity of  antibodies  and  the  HL-A  antigens  leukocyte mem- 
brane in cultures in which suppression was observed (30, 31). Inhibitory anti- 
bodies may be directed to sites other than HL-A, such as antigens controlled 
by a postulated MLC locus (32, 33) or to other receptors on the 1)anphocyte. 
Brain  cells  and  lymphocytes may  share  certain  membrane  determinants, 
It  is known  that  in  mice  the  theta  antigen  of th)anus-derived  1)anphocytes 
is  shared  by brain  cells  (34).  If  tolerance to  brain  is  broken,  isoantibodies 
elicited may cross-react with  receptors on lymphocytes. The brain  has  been 
considered to be an immunologically privileged site (35). The development of a 
tumor  may  allow  immunologically competent  cells  to  penetrate  the  blood- 
brain barrier and incite an immune response. Certain studies on the termina- 
tion of tolerance suggest an alternative possibility (36). When brain cells ac- 
quire tumor antigens, tolerance is broken and antibody is synthesized against 
normal membrane determinants as well as tumor antigens. Some of the anti- 
bodies  elicited may cross-react with  determinants  on  the  lymphocyte mem- 
brane.  The  appearance  of  suppressor  isoantibody  may  reflect  a  protective 
compensatory response  to  antigens  that  elicit  a  population  of  1)~nphocytes 
sensitized to host determinants. This class of antibody, then, may serve as a 
regulator of cell-mediated immunity. 
If we assume that an antibody is the humoral suppressor, several modes of 
action  should  be  considered.  Certain  antibodies  are  lymphocytotoxic in  the 
presence of complement. In our studies  lymphocytes incubated with patient 
IgG fractions and rabbit complement were not killed. In addition, suppressor 
activity was observed even after heat-inactivation of complement. Cytotoxic- 
ity is  therefore unlikely. The possibility  that  inhibitory serum  contains  suf- 
ficient antibodies  of such diverse specificity as  to mask receptor sites  on all 
stimulants  is  also unlikely. Consistent with many recent observations on the 
mechanism  of  immunologic  enhancement,  it  is  most  suitable  to  consider  a 
direct effect on  the  lymphocyte membrane  (31,  37-39).  Cross-reacting  anti- 
body  molecules may suppress  lymphocyte activation  either  by  altering  the 
lymphocyte surface or by directly blocking a membrane receptor site. 1644  CHARACTERIZATION  OF  AN  IM~IUNOSUPPRESSIVE  FACTOR 
The present  studies,  then  suggest  that  impaired  delayed hypersensitivity 
in patients with intracranial tumors follows the development of the neoplasm 
instead  of  preceding  it.  This  suggestion  is  supported  by  the  absence  of  an 
intrinsic cellular defect and the rapid disappearance of the humoral suppressor 
after removal of the tumor. Other workers have reported that  tumor-specific 
blocking activity disappeared shortly after extirpation (40). This observation 
supports the close association between the enhancing and immunosuppressive 
activities in serum. If, in fact, IgG suppressor antibodies regulate the level of 
cell-mediated immunity,  it is  likely that  similar immunosuppressive activity 
will  be  found in  the  sera  of patients  with  other neoplastic  or inflammatory 
diseases who have depressed cellular immunity. 
SUMMARY 
Tumor immunity in patients with primary intracranial  tumors was assessed 
in  relation  to  the  general  status  of  host  immunocompetence.  Lymphocyte 
sensitization  to  tumor-specific membrane  antigens  was  demonstrated  by the 
proliferative response of lymphocytes in the presence of autochthonous tumor 
ceils.  Paradoxically,, one-half of the patients could not be sensitized to a  pri- 
mary antigen, dinitrochlorobenzene; existing delayed hypersensitivity was also 
depressed,  as  measured  bv skin  tests  and  lymphocyte transformation  in  re- 
sponse to common antigens. 
A heat-stable factor in patients' sera blocked cell-mediated tumor immunity. 
In  addition,  these  "enhancing"  sera  consistently suppressed  the  blastogenic 
response of autologous  and  homologous lymphocytes to phytohemagglutinin 
and to membrane antigens on allogeneic cells in the one-way mixed lymphocyte 
culture.  When  patients'  leukocytes were  washed  and  autologous plasma  re- 
placed  with  normal  plasma,  reactivity in  the  mixed  13~nphocyte  culture  in- 
creased to normal values. 
In vitro imnmnosuppressive activity in patients'  plasma or sera correlated 
with depressed delayed hypersensitivity'. After removal of the tumor, suppres- 
sor  activity disappeared.  IgG fractions of patient  sera  contained strong  im- 
munosuppressive activity. These data suggest that the suppressor factor may 
be an  isoantibody elicited by the  tumor  that  also  binds  to receptors on  the 
lymphocyte  membrane.  In  addition  to  specifically  blocking  cell-mediated 
tumor  inmmnity,  enhancing  sera  may  broadly depress  host  immunocompe- 
tence. 
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